In the last 25 years, growing evidence has supported Hsp90 as an exceptional drug target for the treatment of neurodegenerative diseases and cancer, but the associated toxicity has hindered the success of its inhibitors [36]. The gene discussed is HSP90AB1; the disease is cancer.